Search clinical trials for: abiraterone therapy

Total 52225 results

Bayer
Janssen Research & Development, LLC

Completed

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (ERA 223)

Prostatic Neoplasms

Belgium, Spain, Canada, United States, Japan, Russian Federation, France, Finland, Singapore, Australia, Germany, Israel, Netherlands, Norway, Italy, United Kingdom, Poland, Sweden, Brazil
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Prostate Cancer | Advanced Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.; Stand Up To Cancer

Active, not recruiting

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Metastatic Prostate Cancer

United States
Icahn School of Medicine at Mount Sinai
Sanofi; Bayer

Completed

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Prostate Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Prostate Cancer

United States
Fudan University

Active, not recruiting

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Neoadjuvant Therapy | High-risk Prostate Cancer

China
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Dana-Farber Cancer Institute
Janssen Scientific Affairs, LLC

Active, not recruiting

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Prostate Cancer

United States
UNICANCER
Sanofi; European Organisation for Research and Treatment of Cancer - EORTC; I... and other collaborators

Active, not recruiting

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (PEACE1)

Metastatic Prostate Cancer

France, Ireland, Spain, Switzerland, Belgium, Italy, Romania
Amgen

Terminated

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, Sweden, Spain, United Kingdom, Australia, Denmark
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
Lawrence Fong
Merck Sharp & Dohme LLC; Prostate Cancer Foundation; TriSalus Life Sciences,...

Active, not recruiting

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Prostatic Neoplasms

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma in the Soft Tissue | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States, Puerto Rico
Medical Research Council

Active, not recruiting

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Prostate Cancer

United Kingdom, Switzerland
National Cancer Institute, Naples

Active, not recruiting

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Metastatic Castration-resistent Prostate Cancer

Italy
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Prostate Neoplasms

Canada, France, Poland, Ukraine, United Kingdom, China, Belgium, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, Germany, Malaysia, Romania, South Africa, Turkey, Korea, Republic of, Japan, Australia, Netherlands, Sweden, New Zealand and more
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Prostate Cancer

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Active, not recruiting

Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

Prostate Cancer

China
Biosplice Therapeutics, Inc.

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Colorectal Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer

United States, Australia
Duke University
Janssen Pharmaceuticals

Completed

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Prostate Cancer

United States
Montefiore Medical Center

Active, not recruiting

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Prostatic Neoplasms

United States
Instituto do Cancer do Estado de São Paulo
Janssen, LP

Completed

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Prostate Cancer

Brazil
M.D. Anderson Cancer Center

Completed

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
GlaxoSmithKline

Terminated

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Solid Tumours

United States, Spain, Australia, United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (Restore)

Prostate Cancer

United States
UNICANCER

Completed

Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery (CARLHA)

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

France
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Cedars-Sinai Medical Center

Completed

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
United States Department of Defense

Completed

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)

Castration Resistant Metastatic Prostate Cancer

United States
University of Calgary

Terminated

Tolvaptan for Advanced or Refractory Heart Failure

Heart Failure | Hyponatremia

Canada
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Prostatic Neoplasms

United States, Canada
University of Utah

Terminated

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)

Stage IV Prostate Cancer | Metastatic Prostatic Adenocarcinoma | Castration-Sensitive Prostate Carcinoma | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
Universität des Saarlandes

Completed

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE) (SPARE)

Prostate Cancer

Germany
Janssen Research & Development, LLC

Completed

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Prostatic Neoplasms

Brazil
M.D. Anderson Cancer Center
Medivation, Inc.; Janssen Services, LLC

Completed

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Prostate Cancer

United States
Radboud University Medical Center
Janssen-Cilag Ltd.

Completed

Optimizing Abiraterone Therapy (OPTIMUM)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Guangzhou University of Traditional Chinese Medicine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

Prostatic Neoplasms

China
Sanofi

Terminated

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (PRIMCAB)

Prostate Cancer Metastatic

Canada, United States
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Dendreon

Completed

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Hormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States
National Cancer Institute (NCI)

Completed

AMG 386 and Abiraterone for Advanced Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Neoplasm, Prostate | Neoplasm,Prostatic

United States
Janssen Pharmaceutical K.K.

Completed

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Metastatic Castration-Resistant Prostate Cancer

Japan
Lorenzo Livi

Unknown

Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) (ARTO)

Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (RAD1)

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Institut Curie

Unknown

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (SHIVA)

Reccurent/Metastatic Solid Tumor Disease

France
Cougar Biotechnology, Inc.

Completed

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

Prostatic Neoplasms

United Kingdom
University of Vigo
Hospital Clinico Universitario de Santiago; Xunta de Galicia; Ministerio de Educacion...

Completed

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy (MAPEC)

Hypertension

Spain

Search clinical trials for: abiraterone therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations